Nevirapine Accord Healthcare

Nevirapine, the active ingredient in Nevirapine Accord Healthcare, is a non-nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV-1 infection in adults and adolescents by inhibiting viral replication. GNH USA supplies Nevirapine Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication indicated for HIV‑1 infection and is used as part of combination therapy. - HIV‑1 infection (treatment‑naïve adults): reduces plasma viral load when combined with other antiretrovirals. - HIV‑1 infection (treatment‑experienced adults): provides an alternative NNRTI option within a regimen. - HIV‑1 infection (pediatric patients ≥2 years): contributes to viral suppression as part of age‑appropriate combination therapy.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions are frequently reported. - Nausea: gastrointestinal discomfort may occur after dosing. - Fatigue: patients often experience a feeling of tiredness. - Headache: mild to moderate headaches are common.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Hepatotoxicity: liver injury ranging from elevated enzymes to fulminant failure. - Hypersensitivity reactions: including fever, eosinophilia, and systemic symptoms.

Nevirapine requires careful monitoring and specific safety measures. - Monitor liver function: baseline and periodic LFTs are recommended. - Assess for rash: discontinue if a severe skin reaction develops. - Avoid use in patients with known hypersensitivity to NNRTIs. - Use caution in patients with hepatitis B or C co‑infection. - Pregnancy and breastfeeding: risk unknown, weigh benefits versus potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Nevirapine interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may reduce nevirapine plasma levels. - St. John’s wort: induces metabolism, decreasing nevirapine efficacy. - Efavirenz: concurrent use increases risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): may lower nevirapine concentrations. - Anticoagulants (warfarin): nevirapine can increase INR, requiring dose adjustment. - Oral contraceptives: nevirapine may reduce hormonal effectiveness, consider alternative contraception.